Table 1. Baseline characteristics of individual cohorts and all mITT patients.

EOM, every other month; BCVA, best-corrected visual acuity; DA, disc area (1 DA = 2.54 mm2); GA, geographic atrophy.

Sham pooled
(n = 40)
Lampalizumab monthly
(n = 42)
Lampalizumab EOM
(n = 41)
All mITT patients
(n = 123)
Patient demographics
  Age (years), mean (SD)78.5 (7.3)80.4 (7.2)77.2 (7.3)78.7 (7.3)
  Sex (female), n (%)24 (60.0)28 (66.7)18 (43.9)70 (56.9)
  Race (white), n (%)40 (100.0)40 (95.2)41 (100.0)121 (98.4)
Study eye characteristics
  BCVA letters, mean (SD)45.9 (13.4)47.6 (12.8)49.5 (11.0)47.7 (12.4)
  Snellen equivalent (median)20/12520/10020/10020/100
  Total area of GA, DA (SD)3.48 (1.65)3.37 (1.52)3.37 (1.93)3.41 (1.69)
  Total area of GA, mm2 (SD)8.85 (4.18)8.56 (3.86)8.56 (4.90)8.65 (4.30)